Marbotab P 80 mg tablets for dogs
Marbotab P 80 mg tablets for dogs
Authorised
- Marbofloxacin
Product identification
Medicine name:
Marbotab P 80 mg tablets for dogs
Marbotab P 80 mg Tabletten für Hunde
Active substance:
- Marbofloxacin
Target species:
-
Dog
Route of administration:
-
Oral use
Product details
Active substance and strength:
-
Marbofloxacin80.00/milligram(s)1.00Tablet
Pharmaceutical form:
-
Tablet
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QJ01MA93
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Germany
Available in:
-
Germany
Package description:
- (ID4) 200 Tablet: unspecified outer container with 20 Blister (Orientated PolyAmide; Aluminium; PolyVinyl Chloride) each with 10 Tablet, closed with Foil (Aluminium)
- (ID3) 100 Tablet: unspecified outer container with 10 Blister (Orientated PolyAmide; Aluminium; PolyVinyl Chloride) each with 10 Tablet, closed with Foil (Aluminium)
- (ID2) 50 Tablet: unspecified outer container with 5 Blister (Orientated PolyAmide; Aluminium; PolyVinyl Chloride) each with 10 Tablet, closed with Foil (Aluminium)
- (ID1) 20 Tablet: unspecified outer container with 2 Blister (Orientated PolyAmide; Aluminium; PolyVinyl Chloride) each with 10 Tablet, closed with Foil (Aluminium)
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
- CP-Pharma Handelsgesellschaft mbH
Marketing authorisation date:
Manufacturing sites for batch release:
- CP-Pharma Handelsgesellschaft mbH
Responsible authority:
- Federal Office Of Consumer Protection And Food Safety
Authorisation number:
- 401669.00.00
Date of authorisation status change:
Reference member state:
-
Germany
Procedure number:
- DE/V/0173/002
Concerned member states:
-
Hungary
-
Spain
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
